Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Cormedix Inc (CRMD)

Cormedix Inc (CRMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
CorMedix Therapeutics Announces Share Repurchase Program GlobeNewswire - Mon Feb 2, 7:30AM CST

BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.51 (-2.34%)
CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026 GlobeNewswire - Thu Jan 29, 7:30AM CST

BERKELEY HEIGHTS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.51 (-2.34%)
MarketBeat.com
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 MarketBeat - Mon Jan 19, 10:28AM CST

2026 could be a pivotal year for three biotech names, including a standout in the hemodialysis space and two emerging companies with strong pipelines.

EVMN : 28.90 (-0.45%)
ATAI : 3.94 (+2.34%)
CRMD : 7.51 (-2.34%)
Lost Money on CorMedix Inc. (CRMD)? Contact Levi & Korsinsky About Fraud Investigation Newsfile - Wed Jan 14, 9:12AM CST

New York, New York--(Newsfile Corp. - January 14, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into CorMedix Inc. ("CorMedix Inc.") (NASDAQ: CRMD) concerning potential...

CRMD : 7.51 (-2.34%)
CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Fri Jan 9, 7:30AM CST

BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.51 (-2.34%)
CorMedix Therapeutics Announces Leadership and Board Updates GlobeNewswire - Thu Jan 8, 7:05AM CST

BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.51 (-2.34%)
CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates GlobeNewswire - Thu Jan 8, 7:00AM CST

‒ Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒ ‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒ ‒ Expects Q4 Adjusted EBITDA of Between $77...

CRMD : 7.51 (-2.34%)
MarketBeat.com
Why CorMedix Could be the Biopharma Name to Watch Early in 2026 MarketBeat - Tue Dec 23, 2025

CorMedix is a promising biopharma firm in the catheter lock solution space. Continued success for its top products could fuel significant growth into 2026.

CRMD : 7.51 (-2.34%)
MarketBeat.com
MarketBeat’s Top 5 Rated Small-Cap Stocks MarketBeat - Mon Dec 22, 2025

Small-cap stocks are regaining momentum as rate cuts and the end of quantitative tightening drive a renewed risk-on environment.

ATAI : 3.94 (+2.34%)
TRVI : 10.88 (-3.29%)
CRMD : 7.51 (-2.34%)
TREE : 42.65 (-6.98%)
MNMD : 15.02 (+1.01%)
IWM : 264.84 (-0.50%)
CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath GlobeNewswire - Thu Dec 18, 2025

BERKELEY HEIGHTS, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.51 (-2.34%)

Barchart Exclusives

Will Tech Stocks Bounce Back or Should You Sell Them Instead? Barchart - 9 minutes ago
Tech stocks have been under pressure amid concerns over hyperscalers' AI spending spree and selloff in software stocks. Will tech stocks bounce back, or should you sell them instead? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot